Condition
MSI-High
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06362369Phase 1Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06305962Early Phase 1Recruiting
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
NCT05286294Phase 2Active Not Recruiting
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
NCT04787042Phase 1Recruiting
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT05645094Not Yet Recruiting
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Showing all 5 trials